Calidi Biotherapeutics has appointed Corsee Sanders as an independent director on its Board of Directors, effective June 17, 2026. Sanders previously served as Senior Vice President, Global Head of Clinical Operations at Genentech/Roche Holdings for six years, and as Executive Vice President of Development Operations at Juno, later becoming a strategic advisor to the Chief Medical Officer after Celgene acquired Juno. She also acted as Transition Advisor to Bristol Myers Squibb following its acquisition by Celgene, helping integrate Juno's CAR-T cell development organization. Sanders currently holds board seats at Legend Biotech Corporation, Ultragenyx Pharmaceutical Inc., and AltruBio Inc. Calidi shares closed Tuesday at $0.1560, down 2.50%, and were trading down 1.92% to $0.1530 in the pre-market.
Calidi Biotherapeutics Inc.Appointment of experienced biotech executive to board is a positive governance signal
Bristol-Myers Squibb Company
Legend Biotech Corp
Ultragenyx